Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

70839 Origami™ B(DE3)pLysS Competent Cells - Novagen

Origami B host strain derived from a lacZY mutant of BL21 to enable precise control of expression levels using IPTG. T7 lysozyme expression suppresses basal T7 expression.

Origami™ B(DE3)pLysS Competent Cells - Novagen MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
70839
Purchase on Sigma-Aldrich

Przegląd

Replacement Information

Products

Numer katalogowyOpakowanie Ilość/opak.
70839-3 Ampulka plastikowa 0.4 ml
70839-4 Butelka szklana 1 ml
Description
OverviewOrigami™ B host strains carry the same mutations in trxB and gor as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable precise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami strains in one strain background. The mutations in trxB and gor are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with plasmids that can only selected with kanamycin or tetracycline. These strains also include the lon and ompT deficiences of BL21, which increase protein stability.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability.
Genotype: F- ompT hsdSB(rB- mB-) gal dcm lacY1 ahpC (DE3) gor522:: Tn10 trxB pLysS (CamR, KanR, TetR)


This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.




This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
Catalogue Number70839
Brand Family Novagen®
References
Product Information
Components
Guaranteed efficiencyGuaranteed efficiency: > 2 x 10⁶ cfu/μg
Quality LevelMQ100
Applications
Biological Information
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Multiple Toxicity Values, refer to MSDS
Storage ≤ -70°C
Do not freeze Ok to freeze
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numer katalogowy GTIN
70839-3 07790788052836
70839-4 07790788052843

Documentation

Origami™ B(DE3)pLysS Competent Cells - Novagen Certificates of Analysis

TitleLot Number
70839

Brochure

Title
Competent Cell Brochure

Citations

Tytuł
  • Megan M. Kibbey, et al. (2006) Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to IGF-1 binding. Molecular Pharmacology 69, 833-845.
  • James Flint, et al. (2005) Probing the mechanism of ligand recognition in family 29 carbohydrate-binding molecules. Journal of Biological Chemistry 280, 23718-23726.
    		•

    User Protocols

    Title
    TB009 Competent Cells
    TB053 Academic and Non-profit Laboratory Assurance Letter